WHO Warning: Funding Cuts and Healthcare Gaps Threaten 2030 HIV, Hepatitis, and STI Goals

A critical mid-term assessment released by the World Health Organization (WHO) at the 26th International AIDS Conference (AIDS 2026) paints a complex picture of the global campaign against infectious epidemics: while scientific breakthroughs and expanding treatment access have saved tens of millions of lives, severe funding shortfalls, humanitarian crises, and entrenched social inequalities endanger fragile global gains.

Quick summary

• HIV Progress & Barriers: An estimated 32 million people were receiving HIV treatment by late 2025, driving AIDS-related deaths down 57% since 2010. However, 9 million people still lack access, and 2025 donor funding cuts severely disrupted prevention programs like Pre-Exposure Prophylaxis (PrEP).
• Hepatitis Crisis: Viral hepatitis remains one of the world's deadliest threats, claiming 1.3 million lives in 2024. Hepatitis B mortality has jumped 17% since 2015 due to low testing and treatment coverage.
• STI & Drug Resistance Escalation: STI rates are climbing across multiple regions while antimicrobial resistance in gonorrhoea poses an escalating public health threat, prompting WHO to advocate for innovative tools like doxycycline post-exposure prophylaxis (doxy-PEP).
• Strategic Roadmap: Reaching 2030 elimination goals requires embedding HIV, hepatitis, and STI services into primary healthcare networks, expanding game-changing medical technologies like twice-yearly injectable lenacapavir, and empowering community-led programs.

Why it matters

The findings carry urgent implications for public health policy, international development assistance, and healthcare financing worldwide. Uncontrolled transmission of bloodborne and sexually transmitted infections places immense structural strains on national healthcare systems and reduces economic productivity across developing and developed nations alike. Without immediate reinvestment and structural reform, the world risks forfeiting decades of hard-won progress, potentially triggering resurgence cycles that require far higher long-term financial outlays to manage.

Moreover, the report highlights how modern healthcare challenges are deeply interconnected. Rising drug resistance in gonorrhoea serves as a stark warning regarding global antimicrobial resistance (AMR), while persistent gaps in maternal screening risk the lifelong health of newborns. For healthcare providers, policymakers, and communities, the directive is clear: single-disease silos are no longer viable, and long-term success hinges on building resilient, integrated health networks accessible to the most marginalized populations.

Background

In 2022, the World Health Assembly formally adopted the Global Health Sector Strategies (GHSS) on HIV, viral hepatitis, and sexually transmitted infections for the 2022–2030 period. Designed as an actionable framework, the strategies aimed to integrate service delivery, promote universal health coverage, and eradicate all three disease clusters as public health threats by the end of the decade.

Over the past decade, significant achievements were recorded. HIV mortality fell dramatically from its peak, hepatitis C cure regimens revolutionized liver disease management, and several countries successfully eliminated mother-to-child transmission of HIV and syphilis. However, recent geopolitical shifts, economic shocks, and international donor retrenchment in 2025 introduced severe operational headwinds. The newly released WHO report provides a mid-point reality check, published alongside the adoption of the 2026 United Nations High-Level Meeting Political Declaration on HIV/AIDS to recalibrate global health investments for the remaining four years of the strategy.

Key Findings: The Expanding Gap Between Science and Access

The WHO report reveals a stark disparity between scientific capability and field implementation. On HIV, overall global metrics demonstrate substantial long-term success: new HIV infections have fallen by 42% since 2010, while AIDS-related deaths dropped by 57%. By the end of 2025, 32 million individuals were maintained on life-saving antiretroviral therapy.

Yet, structural vulnerabilities are expanding. Approximately 9 million people living with HIV remain entirely without treatment access. New infections are surging in key demographic groups, including men who have sex with men, sex workers, people who inject drugs, transgender individuals, and incarcerated populations. Compounding these challenges, abrupt reductions in international donor financing throughout 2025 forced key prevention programs to scale back operations. Preliminary health data indicates a measurable drop in PrEP uptake across several vulnerable communities after external funding streams dried up.

Viral Hepatitis: A Growing Silent Mortality Crisis

While public attention often focuses on HIV, viral hepatitis remains one of the world's most deadly infectious threats. Despite a 32% decline in new hepatitis B infections and a 12% drop in hepatitis C deaths since 2015, total mortality caused by viral hepatitis reached an estimated 1.3 million lives in 2024.

Crucially, deaths directly linked to hepatitis B have climbed by 17% since 2015. Highly effective antiviral treatments and protective vaccines exist, yet diagnostic coverage remains profoundly deficient. Most individuals infected with hepatitis B or C remain unaware of their status until severe liver damage or hepatocellular carcinoma develops. In response, WHO's World Hepatitis Day initiative, under the banner "Hepatitis: Let's Break It Down," urges nations to eliminate the high out-of-pocket costs, social stigma, and institutional delays that keep testing and treatment out of reach.

Sexually Transmitted Infections and Antimicrobial Resistance

Progress against sexually transmitted infections remains uneven globally. While maternal syphilis screening and treatment have improved in several regions and human papillomavirus (HPV) vaccination coverage has registered modest gains, total STI case counts are increasing in many jurisdictions.

A major concern highlighted by WHO is the rising prevalence of multidrug-resistant gonorrhoea. As first-line antibiotic therapies lose efficacy against mutating strains, clinical treatment options are narrowing. To combat this trend and curb bacterial STI transmission, WHO has recommended new targeted strategies, such as doxycycline post-exposure prophylaxis (doxycycline PEP) for high-risk populations, alongside calls for enhanced diagnostic infrastructure and surveillance systems.

Game-Changing Innovations and Primary Healthcare Integration

To overcome operational bottlenecks, WHO emphasizes two major vectors of progress: medical innovation and primary care integration. Among key breakthroughs is lenacapavir, a WHO-recommended twice-yearly injectable antiretroviral for HIV prevention. Lenacapavir is currently being introduced in 10 countries, with rollout planned for an additional 14 nations, offering a powerful alternative for individuals unable to maintain daily oral PrEP regimens.

Simultaneously, WHO advocates for multi-disease testing platforms and the complete integration of HIV, hepatitis, and STI services into routine primary healthcare networks, tuberculosis clinics, maternal-child health services, and noncommunicable disease management. Countries adopting integrated health platforms have reported superior outcomes, particularly in achieving WHO validation for the triple elimination of mother-to-child transmission of HIV, syphilis, and hepatitis B.

To support national implementation, WHO released consolidated HIV service delivery guidelines and updated HIV surveillance guidance. These documents equip health authorities with operational framework standards to streamline routine monitoring, optimize clinical workflows, and deploy community-generated data to improve healthcare delivery accountability.

Qnews24h insight

The WHO report underscores an uncomfortable reality in global public health: medical technology alone cannot compensate for declining political willpower and unstable budget allocations. The scientific tools required to end HIV, viral hepatitis, and STIs as epidemic threats exist today. Highly effective antivirals, curative hepatitis C drugs, long-acting preventive injectables like lenacapavir, and protective vaccines are fully proven. However, relying on high-tech interventions without fortifying underlying public health infrastructure creates fragile progress that collapses the moment donor priorities shift.

The donor pullback observed in 2025 demonstrates the vulnerability of top-down financing models. If national governments fail to transition these specialized programs into domestic primary healthcare budgets and leverage community-led health networks, the 2030 elimination targets will remain unfulfilled targets. Sustainable progress demands predictable public health funding, reduced pharmaceutical pricing barriers, and aggressive legislative protection for key populations facing social discrimination.

Sources

• World Health Organization (WHO): Integration, innovation and community leadership key to ending HIV, hepatitis and STIs (Published July 2026).
• Global Health Sector Strategies on HIV, viral hepatitis and sexually transmitted infections 2022–2030, World Health Organization.

Frequently Asked Questions

What are the primary targets of the WHO Global Health Sector Strategies for 2022–2030?

The primary target of the GHSS 2022–2030 is to eliminate HIV, viral hepatitis, and sexually transmitted infections (STIs) as public health threats by 2030, while promoting universal health coverage, health equity, and primary healthcare integration across WHO Member States.

Why are hepatitis B deaths increasing despite existing treatments?

Hepatitis B deaths have increased by 17% since 2015 primarily due to low global rates of diagnosis and treatment coverage. Although effective viral suppression drugs are available, systemic healthcare barriers, financial costs, and a lack of routine screening leave millions unaware of their infection until fatal liver complications develop.

What is lenacapavir and how does it assist in HIV prevention?

Lenacapavir is a WHO-recommended long-acting antiretroviral medication administered as an injection twice a year. It serves as a breakthrough alternative to daily oral PrEP pills, significantly improving adherence and prevention coverage for individuals at high risk of HIV infection.